Get access

Epidermal growth factor receptor as a therapeutic target in veterinary oncology

Authors

  • G. T. Bergkvist,

    Corresponding author
    1. Royal (Dick) School of Veterinary Studies and Roslin Institute, Division of Veterinary Clinical Sciences, The University of Edinburgh, Hospital for Small Animals, Easter Bush Veterinary Centre, Roslin, Midlothian, UK
    Search for more papers by this author
  • D. A. Yool

    1. Royal (Dick) School of Veterinary Studies and Roslin Institute, Division of Veterinary Clinical Sciences, The University of Edinburgh, Hospital for Small Animals, Easter Bush Veterinary Centre, Roslin, Midlothian, UK
    Search for more papers by this author

G. T. Bergkvist
Royal (Dick) School of Veterinary Studies and Roslin Institute
Division of Veterinary Clinical Sciences
The University of Edinburgh
Hospital for Small Animals
Easter Bush Veterinary Centre
Roslin, Midlothian EH25 9RG, UK
e-mail: g.t.bergkvist@sms.ed.ac.uk

Abstract

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that stimulates cell proliferation and survival and becomes dysregulated in a range of solid tumours in man. It is recognized as a key oncogenic driver and has become a favoured therapeutic target and a prognostic and predictive marker of cancer in man. In animals, EGFR dysregulation is emerging as a potential factor in the development of a number of naturally occurring tumours including mammary, lung, glial and epithelial cancers. Comparative analyses suggest that these diseases share many features with equivalent diseases in man and EGFR may have value as a prognostic or a biological marker of animal disease. There is still little direct evidence that EGFR is a critical oncogenic driver in naturally occurring animal disease and there are no veterinary trials of EGFR-targeted therapy. These will be critical steps in establishing a role for EGFR in veterinary oncology.

Ancillary